Ligand-targeted liposomes directed against pathological vasculature.
The development of liposomes targeted to angiogenic endothelial cells offers exciting prospects for intervention in cancer and inflammation. Several proteins are (strongly) over-expressed on angiogenic endothelial cells as compared to the quiescent endothelium, and could potentially serve as targets for site-specific drug delivery. In this contribution particular attention is given to the design of targeted long-circulating liposomes directed against the alpha v beta 3-integrin protein.
Schiffelers
Raymond M
RM
Dept of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, TB Utrecht, 3508, The Netherlands.
Molema
Grietje
G
ten Hagen
Timo L M
TL
Janssen
Adriënne P C A
AP
Schraa
Astrid J
AJ
Kok
Robbert J
RJ
Koning
Gerben A
GA
Storm
Gert
G
D002478:Cells, Cultured; D004317:Doxorubicin / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology; D006801:Humans; D007249:Inflammation; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D016023:Integrins / Q000378:metabolism; D008024:Ligands; D008081:Liposomes / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009842:Oligopeptides / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000378:metabolism; D014471:Umbilical Veins / Q000166:cytology
D039302:Integrin alphaVbeta3; D016023:Integrins; D008024:Ligands; D008081:Liposomes; D009842:Oligopeptides; D011092:Polyethylene Glycols; C047981:arginyl-glycyl-aspartic acid; D004317:Doxorubicin